NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP
Apyx Medical Corp. APYX
17 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
USD 52.8M
Revenue, FY2025 · full 17-year series below
Revenue $M
Net income $M
FY2025 · Revenue 52.8 · Net income -11.2
Compound annual growth
Revenue compounded at +13.8% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−21 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -12.2% · Net -21.0%
ROE
FY2025 · ROE -78.0%
Each USD of equity lost 78 cents this year.
The 17-year record
17 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.1 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 | −0.0 | −0.0 | 0.0 |
| EBITDA $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 | 0.0 | −0.0 | 0.0 |
| Income tax $B | 0.0 | 0.0 | −0.0 | 0.0 | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 | 0.0 | 0.0 | −0.0 | 0.0 | 0.0 | −0.0 | 0.0 |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | 0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 | 0.0 | −0.0 | 0.0 |
| Free cash flow $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 | −0.0 | −0.0 |
| EPS, diluted $ | · | · | −0.54 | −0.67 | −0.44 | −0.35 | −0.58 | 1.83 | −0.17 | −0.15 | 0.24 | −1.03 | −0.40 | 0.03 | 0.01 | −0.09 | 0.03 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | −78.0 | −114.7 | −58.2 | −50.8 | −25.8 | −17.6 | −24.9 | 114.9 | −21.0 | −46.5 | −43.1 | −168.0 | −20.7 | 2.7 | 0.5 | −7.2 | 2.8 |
| Shares out B | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 | 17.56 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 83 reconciliationsAUDITED
Reconciled in 17 of 19 fiscal years. 12 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2009